| pubmed-article:15046591 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15046591 | lifeskim:mentions | umls-concept:C0014442 | lld:lifeskim |
| pubmed-article:15046591 | lifeskim:mentions | umls-concept:C0005576 | lld:lifeskim |
| pubmed-article:15046591 | lifeskim:mentions | umls-concept:C1522240 | lld:lifeskim |
| pubmed-article:15046591 | lifeskim:mentions | umls-concept:C0185125 | lld:lifeskim |
| pubmed-article:15046591 | lifeskim:mentions | umls-concept:C0680536 | lld:lifeskim |
| pubmed-article:15046591 | pubmed:issue | Pt 2 | lld:pubmed |
| pubmed-article:15046591 | pubmed:dateCreated | 2004-3-29 | lld:pubmed |
| pubmed-article:15046591 | pubmed:abstractText | Biocatalysis is a useful tool in the provision of chiral technology and extremophilic enzymes are just one component in that toolbox. Their role is not always attributable to their extremophilic properties; as with any biocatalyst certain other criteria should be satisfied. Those requirements for a useful biocatalyst will be discussed including issues of selectivity, volume efficiency, security of supply, technology integration, intellectual property and regulatory compliance. Here we discuss the discovery and commercialization of an L-aminoacylase from Thermococcus litoralis, the product of a LINK project between Chirotech Technology and the University of Exeter. The enzyme was cloned into Escherichia coli to aid production via established mesophilic fermentation protocols. A simple downstream process was then developed to assist in the production of the enzyme as a genetically modified-organism-free reagent. The fermentation and downstream processes are operated at the 500 litre scale. Characterization of the enzyme demonstrated a substrate preference for N-benzoyl groups over N-acetyl groups. The operational parameters have been defined in part by substrate-concentration tolerances and also thermostability. Several examples of commercial biotransformations will be discussed including a process that is successful by virtue of the enzyme's thermotolerance. | lld:pubmed |
| pubmed-article:15046591 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15046591 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15046591 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15046591 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15046591 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15046591 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15046591 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15046591 | pubmed:issn | 0300-5127 | lld:pubmed |
| pubmed-article:15046591 | pubmed:author | pubmed-author:BrownR CRC | lld:pubmed |
| pubmed-article:15046591 | pubmed:author | pubmed-author:KingGG | lld:pubmed |
| pubmed-article:15046591 | pubmed:author | pubmed-author:LittlechildJ... | lld:pubmed |
| pubmed-article:15046591 | pubmed:author | pubmed-author:TaylorI NIN | lld:pubmed |
| pubmed-article:15046591 | pubmed:author | pubmed-author:BycroftMM | lld:pubmed |
| pubmed-article:15046591 | pubmed:author | pubmed-author:LloydM CMC | lld:pubmed |
| pubmed-article:15046591 | pubmed:author | pubmed-author:ToogoodH SHS | lld:pubmed |
| pubmed-article:15046591 | pubmed:author | pubmed-author:PraquinCC | lld:pubmed |
| pubmed-article:15046591 | pubmed:author | pubmed-author:TaylorS J CSJ | lld:pubmed |
| pubmed-article:15046591 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15046591 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:15046591 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15046591 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15046591 | pubmed:pagination | 290-2 | lld:pubmed |
| pubmed-article:15046591 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:meshHeading | pubmed-meshheading:15046591... | lld:pubmed |
| pubmed-article:15046591 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15046591 | pubmed:articleTitle | Application of thermophilic enzymes in commercial biotransformation processes. | lld:pubmed |
| pubmed-article:15046591 | pubmed:affiliation | Dowpharma, Chirotech Technology Ltd, 321 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K. itaylor@dow.com | lld:pubmed |
| pubmed-article:15046591 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15046591 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15046591 | lld:pubmed |
